Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model

Journal of Invasive Cardiology

Volumn 19, Issue 3, 2007, Pages 109-112

  Tsuchikane, Etsuo ^a   Suzuki, Takeshi ^b   Katoh, Osamu ^a   Suzuki, Takahiko ^a  

^a Toyohashi Heart Center Toyohashi   (Japan)

^b Toyokawa City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; DRUG ELUTING STENT; DRUG MECHANISM; FOLLOW UP; HISTOPATHOLOGY; IMPLANTATION; INFLAMMATION; NONHUMAN; RESTENOSIS; SCORING SYSTEM; SWINE;

ANIMALS; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HYPERPLASIA; METALS; POLYMERS; STENTS; SWINE; TETRAZOLES; TUNICA INTIMA; VASCULITIS;

EID: 33847666012     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004:109:634-640.
2. Virmani R, Farb A, Kolodgie FD. Histopathologic alterations after endovascular radiation and antiproliferative stents: Similarities and differences. Herz 2002;27:1-6.
3. Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
4. Nishi T, Tabusa F, Tanaka T, et al. Studies on 2-oxo-quinolinone derivatives as blood platelet aggregation inhibitors IV. Synthesis and biological activity of metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxyl]-2-oxo-1, 2, 3, 4-tetrahydroquinolinone (OPC-13013). Chem Pharm Bull (Tokyo) 1985;33:1140-1147.
5. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung Drug Res 1985;35:1144-1149.
6. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-26.
7. Kozuma K, Hara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J 2001;141:124-130.
8. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-2832.
9. Tsuchikane E, Kobayashi T, Awata N. The potential of cilostazol in interventional cardiology. Curr Interv Cardiol Rep 2000;2:143-148.
10. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Phamacol 1992;20:900-906.
11. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation for human aortic vascular smooth muscle cells, accompanied by induction of p.53 and p-21. Hypertension 2000;35:237-243.
12. Morishita R, Higaki J, Hayashi S, et al. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibotor. Diabetologia 1997;40:1053-1061.
13. Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanies by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-1042.
14. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: Are human and animal studies comparable? Heart 2003;89:133-138.
15. Suzuki T, Kopia G, Hayashi S, et al. Stent-base delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
16. Schwartz RS, Huber KC, Murhy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
17. Carter A, Aggarwal M, Kopia G, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-624.
18. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitazel via a polymer-coated stent. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
19. Kollum M, Farb A, Schreiber R, et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005;64:85-90.
20. Nakamura T, Hagiya M, Nishizawa T, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-443.
21. Morishita R, Nakamura S, Nakamura Y, et al. Potential role of an endothelium-specific growth factor, hepatocyte growth factor on endothelial damage in diabetes. Diabetes 1997;46:138-142.
22. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.